In a report released today, Joseph Pantginis from H.C. Wainwright initiated coverage with a Buy rating on Aravive Inc (ARAV – Research Report) and a price target of $18.00. The company’s shares closed last Monday at $6.54.
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -13.6% and a 26.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Aravive Inc has an analyst consensus of Moderate Buy, with a price target consensus of $16.50, representing a 151.8% upside. In a report issued on September 27, Piper Jaffray also maintained a Buy rating on the stock with a $15.00 price target.
Based on Aravive Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.04 million. In comparison, last year the company had a GAAP net loss of $6.55 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARAV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.